论文部分内容阅读
目的:探讨血清CA125在卵巢上皮性癌中的诊断、鉴别诊断意义及手术、术后CP方案化疗后的下降规律。方法:回顾性分析171例卵巢上皮性癌新发病例的临床及病理资料,选取同期其他妇科疾病病例对比分析,并探讨其经手术、CP方案化疗后血清CA125的下降规律。结果:血清CA125在几种妇科疾病中均有不同程度的升高,卵巢上皮性癌血清CA125明显高于其他几种疾病。结论:血清CA125对卵巢上皮性癌具有重要的诊断及鉴别诊断意义,其在卵巢上皮性癌经手术、术后CP方案化疗后大约在(76±28)天相当于术后经0～6个疗程降至正常,故临床上术后常行6～8个疗程CP方案化疗。
Objective: To investigate the diagnostic value of serum CA125 in epithelial ovarian cancer, the significance of differential diagnosis and the declination rule of postoperative chemotherapy after chemotherapy. Methods: The clinical and pathological data of 171 newly diagnosed cases of epithelial ovarian cancer were retrospectively analyzed. The contrastive analysis of other gynecological diseases in the same period was conducted. The declination of serum CA125 after operation and CP regimen was discussed. Results: Serum CA125 increased in some degree in several gynecological diseases. The serum level of CA125 in ovarian epithelial carcinoma was significantly higher than those in other diseases. CONCLUSION: Serum CA125 is an important diagnostic and differential diagnostic value for epithelial ovarian cancer. It is effective in ovarian epithelial carcinoma after operation. The postoperative CP chemotherapy is equivalent to about 76 days (28 ± 28 days) Course of treatment dropped to normal, so clinically postoperative routine 6 to 8 CP regimen chemotherapy.